- Report
- May 2024
- 130 Pages
Global
From €5907EUR$6,499USD£5,058GBP
- Report
- May 2024
- 128 Pages
Global
From €5907EUR$6,499USD£5,058GBP
- Report
- October 2024
- 331 Pages
Global
From €7226EUR$7,950USD£6,187GBP
- Report
- February 2022
- 220 Pages
Global
From €8635EUR$9,500USD£7,394GBP
- Report
- March 2024
- 159 Pages
Global
From €7226EUR$7,950USD£6,187GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €454EUR$500USD£389GBP
Corlanor (ivabradine) is a cardiovascular drug used to treat chronic heart failure. It works by slowing the heart rate, which helps reduce the strain on the heart. Corlanor is a selective inhibitor of the I(f) current, which is a type of electrical current in the heart. By blocking this current, Corlanor helps reduce the heart rate and improve the heart's ability to pump blood. Corlanor is approved for use in the United States, Europe, and other countries.
Corlanor is marketed by Amgen, a biopharmaceutical company based in the United States. Other companies in the Corlanor market include Novartis, Sanofi, and AstraZeneca. Show Less Read more
